Zelgen Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 1,055

Employees

  • Stock Symbol
  • 688266

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $11.08
  • (As of Friday Closing)

Zelgen General Information

Description

Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.

Contact Information

Website
www.zelgen.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • No. 209, Chenfeng Road
  • Kunshan, Jiangsu 215300
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • No. 209, Chenfeng Road
  • Kunshan, Jiangsu 215300
  • China
+86 0512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zelgen Stock Performance

As of 20-Nov-2026, Zelgen’s stock price is $11.08. Its current market cap is $2.93B with 265M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.08 $11.59 $10.88 - $23.58 $2.93B 265M 3.94M $0.31

Zelgen Financials Summary

As of 30-Sep-2026, Zelgen has a trailing 12-month revenue of $254M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 4,096,414 3,369,826 2,083,922 1,780,524
Revenue 254,406 112,703 74,275 54,621
EBITDA 78,484 (20,803) (17,956) (36,899)
Net Income 82,513 (22,659) (19,209) (39,376)
Total Assets 493,370 424,369 411,585 407,303
Total Debt 83,514 161,899 142,360 125,321
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zelgen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zelgen‘s full profile, request access.

Request a free trial

Zelgen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for
Drug Discovery
Kunshan, China
1,055 As of 2025

Cerdanyola, Spain
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zelgen Competitors (14)

One of Zelgen’s 14 competitors is Ability Pharma, a Private Equity-Backed company based in Cerdanyola, Spain.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ability Pharma Private Equity-Backed Cerdanyola, Spain
Genentech Formerly VC-backed South San Francisco, CA
Gilead Formerly VC-backed Foster City, CA
Merck & Co. Corporation Rahway, NJ
Pfizer Pakistan Corporation Karachi, Pakistan
You’re viewing 5 of 14 competitors. Get the full list »

Zelgen Patents

Zelgen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026124659-A1 Dicarbonyl inhibitor, preparation method therefor and use thereof Pending 13-Dec-2024
WO-2026021499-A1 Haloalkylene substituted cycloalkyl or heterocyclic inhibitor, and preparation method therefor and use thereof Pending 24-Jul-2024
US-20250388703-A1 Multi-specific molecules and mentod of use and making thereof Pending 20-Jun-2024
WO-2025208342-A1 Method for preparing high-purity and low-residue recombinant human thrombin and use thereof Pending 02-Apr-2024
WO-2025162477-A1 Multispecific antibody containing lrrc15 antigen-binding domain Pending 04-Feb-2024
To view Zelgen’s complete patent history, request access »

Zelgen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zelgen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Zelgen‘s full profile, request access.

Request a free trial

Zelgen Investments (1)

Zelgen’s most recent deal was a PE Growth/Expansion with Gene Chem for . The deal was made on 30-Jul-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Gene Chem 30-Jul-2020 PE Growth/Expansion Laboratory Services (Healthcare)
To view Zelgen’s complete investments history, request access »

Zelgen ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

43.13 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Zelgen’s complete esg history, request access »

Zelgen FAQs

  • When was Zelgen founded?

    Zelgen was founded in 2009.

  • Where is Zelgen headquartered?

    Zelgen is headquartered in Kunshan, China.

  • What is the size of Zelgen?

    Zelgen has 1,055 total employees.

  • What industry is Zelgen in?

    Zelgen’s primary industry is Drug Discovery.

  • Is Zelgen a private or public company?

    Zelgen is a Public company.

  • What is Zelgen’s stock symbol?

    The ticker symbol for Zelgen is 688266.

  • What is the current stock price of Zelgen?

    As of 20-Nov-2026 the stock price of Zelgen is $11.08.

  • What is the current market cap of Zelgen?

    The current market capitalization of Zelgen is $2.93B.

  • What is Zelgen’s current revenue?

    The trailing twelve month revenue for Zelgen is $254M.

  • Who are Zelgen’s competitors?

    Ability Pharma, Genentech, Gilead, Merck & Co., and Pfizer Pakistan are some of the 14 competitors of Zelgen.

  • What is Zelgen’s annual earnings per share (EPS)?

    Zelgen’s EPS for 12 months was $0.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process